JPMorgan Chase & Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by JPMorgan Chase & Co. on January 17, 2023. The report discloses a corporate governance event regarding the election of a new director.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial performance data.
Material Changes
The material change reported is the election of Alicia Boler Davis as a director of JPMorgan Chase & Co., effective March 20, 2023. Ms. Davis is currently the Chief Executive Officer of Alto Pharmacy. She was also elected as a director of JPMorgan Chase Bank, N.A., and a manager of JPMorgan Chase Holdings LLC.
Guidance, Outlook, and Risks
The filing does not contain management commentary, financial guidance, outlook, or specific risk factors. The appointment of Ms. Davis to specific board committees will be disclosed at a later date when determined.
Key Facts for Investor Verification
- Effective date of the new director appointment is March 20, 2023.
- Alicia Boler Davis is the CEO of Alto Pharmacy.
- Ms. Davis holds concurrent roles as a director of JPMorgan Chase Bank, N.A., and manager of JPMorgan Chase Holdings LLC.
- Specific board committee assignments for Ms. Davis are pending and will be disclosed later.